For the quarter ending 2025-09-30, UNCY made $6,554K in revenue. -$6,011K in net income. Net profit margin of -91.71%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 2,964 | 1,750 | 6,051 | 3,045 |
| General and administrative | 4,378 | 5,213 | 3,182 | 3,206 |
| Total operating expenses | 7,342 | 6,963 | 9,233 | 6,251 |
| Loss from operations | -7,342 | -6,963 | -9,232 | -6,251 |
| Interest income | 279 | 155 | 192 | 416 |
| Interest expense | 15 | 13 | 20 | 15 |
| Change in fair value of warrant liability | -1,067 | -374 | 12,183 | -1,754 |
| Total other income (expenses) | 1,331 | 516 | -12,011 | 2,155 |
| Net loss | -6,011 | -6,447 | -21,244 | -4,096 |
| Dividend to series b-1 preferred stockholders | - | 0 | - | - |
| Dividends on series b-1 preferred stock | - | - | 3,407 | - |
| Net income attributable to participating securities | - | 0 | - | - |
| Net loss attributable to common stockholders | -6,011 | -6,447 | -18,385 | -4,096 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.33 | -0.52 | -0.295 | -0.05 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.33 | -0.52 | -0.18 | -0.05 |
| Weighted-average shares outstanding used in computing net loss per share, basic (in shares) | 18,065,389 | 12,302,059 | -29,936,447.5 | 88,943,212 |
| Weighted-average shares outstanding used in computing net loss per share,diluted (in shares) | 18,065,389 | 12,302,059 | -58,005,468 | 88,943,212 |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)